jRCT2061240045招募中不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND study)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 23
- 主要终点
- Change in proteinuria (urine protein:creatinine ratio [UPCR])
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Male and female subjects aged >= 18 years at the time of signing the informed consent form (ICF) prior to initiation of any study specific activities/procedures.
- •Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. A pseudonymized copy of the report must be available for review by the Sponsor or designee prior to randomization. If biopsy report within 10 years is not available, re-biopsy may be permitted upon discussion with the Sponsor.
- •eGFR >= 30 mL/min/1.73m2 at Screening based on the 2021 CKD-EPI equation.
- •Total urine protein >= 1.0 g/day or UPCR >= 0.7 g/g (700 mg/g), as measured from an adequate 24-hour urine collection at Screening by a central laboratory.
- •Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to Screening unless intolerant to ACEi and ARB. May also be on a stable and well tolerated dose of SGLT2i, ERAs, and/or MRAs for at least 12 weeks prior to Screening for the treatment of IgAN. Subjects are expected to stay on a stable dose of ACEi, ARB, SGLT2i, ERAs, and/or MRAs for the duration of the study.
- •Screening weight of 45 to 150 kg.
- •Men and women of childbearing potential (WOCBP; per Clinical Trials Facilitation and Coordination Group [CTFG] 2020) must agree to follow protocol-specified contraception guidance from Screening through approximately 5 half-lives (24 weeks) after the final dose of study drug. Use of hormonal contraceptive agents must have been initiated > 1 month prior to first dose of study drug.
- •Provide written informed consent and be willing to comply with study visits and procedures.
排除标准
- •Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, autoimmune disorders or neoplasias.
- •Diagnosis of IgA Vasculitis.
- •Current or history of nephrotic syndrome.
- •Average blood pressure > 150/90 mm Hg (systolic/diastolic) from 3 readings obtained at the initial Screening visit. If blood pressure is too high, the 3 readings may be repeated once within the Screening period if clinically appropriate as per the Investigator.
- •Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on KDIGO guidelines.
- •Chronic Kidney Disease, either clinically suspected or based on biopsy, resulting from any condition or another glomerulopathy/podocytopathy other than IgAN.
- •History of Type 1 Diabetes.
- •Subjects with Type 2 diabetes are excluded if any of the following are present:
- •Screening HbA1c (glycated hemoglobin) of > 8%.
- •Evidence of diabetic changes on kidney biopsy, performed for any reason.
- •History of diabetic microvascular disease (retinopathy, neuropathy, nephropathy) and/or macrovascular disease (atherosclerotic heart disease, peripheral vascular disease, cerebrovascular disease).
- •Unstable anti-diabetic regimen.
- •Prior exposure to any antibody directed against APRIL.
- •History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis, including a history of allergy or hypersensitivity to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody.
- •Received an investigational new drug within 28 days or 5 half-lives, whichever is longer, prior to Screening.
- •Received systemic corticosteroid therapy including budesonide (Tarpeyo/Kinpeygo) for > 14 days within 12 weeks prior to Screening.
- •Use of systemic immunosuppressant medications.
- •Any confirmed or suspected immunosuppressive or immune-deficient state, including but not limited to common variable immunodeficiency (CVID), HIV infection or asplenia, history of bone marrow or organ transplantation with exception of corneal transplants.
- •Current severe infection requiring antimicrobials or history of recurrent, severe, infections as determined by the Investigator.
- •Positive serology test for hepatitis A virus IgM antibodies (anti-HAV IgM), hepatitis B surface antigen (HBsAg), detectable hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) antibodies (subjects who completed treatment and are persistently antibody be allowed), or antibodies to HIV-1 and/or HIV-2 at Screening.
- •Received a live vaccination within 12 weeks prior to Screening or plan to have a live vaccination within 6 months after the last dose of study drug.
- •History of malignancy unless cancer free for at least 5 years or non-melanoma skin cancer that was completely resected. A subject with curatively treated cervical carcinoma in situ is eligible for the study. Subjects with low-risk prostate cancer (i.e., Gleason score < 7 and prostate specific antigen < 10 ng/mL) are allowed.
- •Pregnancy or breastfeeding or intent to become pregnant or to donate sperm during the study period and until 24 weeks after last dose.
- •History or evidence of any other clinically significant disorder, condition, disease, or laboratory finding that, in the Investigator's assessment, would place the subject at unacceptable risk, limit compliance with study requirements, or confound interpretation of study results.
- •IgG levels < 6 g/L at Screening.
- •Participation in another interventional trial with an investigational agent/device is prohibited during the course of this study.
结局指标
主要结局
Change in proteinuria (urine protein:creatinine ratio [UPCR])
时间窗: from Baseline to Week 40
Based on 24-hour urine collection
次要结局
- Change from Baseline to Week 104 in eGFR using the CKD-EPI 2021 creatinine equation(Baseline to Week 104)
研究者
相似试验
进行中（未招募）
1 期
Efficacy of immunoglobulins in pediatric early-onset corticosteroid nephrotic syndromeChildhood-Onset steroid-dependent nephrotic syndromeMedDRA version: 20.1Level: PTClassification code 10029164Term: Nephrotic syndromeSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-000826-36-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)90
已完成
3 期
Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trialReumatoid Arthritis1000381610023213NL-OMON40517Boehringer Ingelheim2
进行中（未招募）
不适用
Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trialmoderately to severely active rheumatoid arthritisMedDRA version: 16.1Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870MedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-002622-23-ESBoehringer Ingelheim International GmbH250
进行中（未招募）
不适用
Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trialmoderately to severely active rheumatoid arthritisMedDRA version: 16.1Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870MedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-002622-23-NLBoehringer Ingelheim International GmbH250
进行中（未招募）
1 期
Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trialmoderately to severely active rheumatoid arthritisMedDRA version: 17.0Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 100000004870MedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-002622-23-BEBoehringer Ingelheim International GmbH97